Jazz Pharmaceuticals plc – (JAZZ) Holdings Trimmed by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC lowered its holdings in shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 29.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,430 shares of the specialty pharmaceutical company’s stock after selling 1,000 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Jazz Pharmaceuticals were worth $327,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Toronto Dominion Bank increased its position in shares of Jazz Pharmaceuticals by 12.4% during the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares during the period. Advisor Group Inc. increased its position in shares of Jazz Pharmaceuticals by 62.4% during the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 550 shares during the period. SG Americas Securities LLC increased its position in shares of Jazz Pharmaceuticals by 13.0% during the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock valued at $215,000 after purchasing an additional 159 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $227,000. Finally, Intl Fcstone Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $230,000. 90.73% of the stock is currently owned by hedge funds and other institutional investors.

JAZZ has been the topic of several research analyst reports. UBS Group reiterated a “buy” rating and set a $172.00 price target (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. BMO Capital Markets restated a “buy” rating and issued a $196.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. JPMorgan Chase & Co. restated a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 18th. Royal Bank of Canada restated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, September 15th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, October 26th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $181.68.

In related news, SVP Iain Mcgill sold 8,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Patrick G. Enright sold 9,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The disclosure for this sale can be found here. Insiders have sold 17,552 shares of company stock worth $2,399,643 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at $142.14 on Thursday. Jazz Pharmaceuticals plc – has a twelve month low of $112.52 and a twelve month high of $163.75. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $8,580.00, a price-to-earnings ratio of 23.42, a PEG ratio of 0.73 and a beta of 0.97.

ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals plc – (JAZZ) Holdings Trimmed by Franklin Street Advisors Inc. NC” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/11/jazz-pharmaceuticals-plc-jazz-holdings-trimmed-by-franklin-street-advisors-inc-nc.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit